This work presents direct evidence that the bcl-2 gene is transcriptionally regulated by nuclear factor-kB (NF-kB) and directly links the TNF-a/NF-kB signaling pathway with Bcl-2 expression and its pro-survival response in human prostate carcinoma cells. DNase I footprinting, gel retardation and supershift analysis identi®ed a NFkB site in the bcl-2 p2 promoter. In the context of a minimal promoter, this bcl-2 p2 site 1 increased transcription 10-fold in the presence of the p50/p65 expression vectors, comparable to the increment observed with the consensus NF-kB site, while for the full p2 promoter region transcriptional activity was increased sixfold by over-expression of NF-kB, an eect eliminated by mutating the bcl-2 p2 site 1. The expression of Bcl-2 has been linked to the hormone-resistant phenotype of advanced prostate cancer. Here we show that an increase in the level of expression of Bcl-2 in the human prostate carcinoma cell line LNCaP observed in response to hormone withdrawal is further augmented by TNF-a treatment, and this eect is abated by inhibitors of NFkB. Concomitantly, bcl-2 p2 promoter studies in LNCaP cells show a 40-fold increase in promoter activity after stimulation with TNF-a in the absence of hormone. Oncogene (2001) 20, 7342 ± 7351.
Introduction
Over the last few years, there has been mounting evidence that apoptosis signaling pathways are involved in many disease states, including cancer. A key player in apoptosis is the Bcl-2 family of proteins, which can be divided into either anti-apoptosis (Bcl-2, Bcl-X L , Bcl-W, A1 and Mcl-1) or pro-apoptosis (Bax, Bid, Bad, Bak, Bic, Bok, Bcl-XS, and Hrk) members (reviewed in Gross et al., 1999) . Many studies propose that the relative levels of these pro-apoptotic and antiapoptotic proteins within a cell determine whether the cell lives or dies in response to apoptotic signaling (Oltvai et al., 1993; Oltvai and Korsmeyer, 1994 ). The precise manner in which Bcl-2 confers protection against apoptosis is still unclear; however, it is thought to directly or indirectly prevent the release of cytochrome c from the mitochondria, which in turn prevents the activation of Apaf-1 and the downstream caspases (Zou et al., 1997) .
Although many studies have investigated the antiapoptosis role of Bcl-2, little is known about the transcriptional regulation of bcl-2. It has been known for some time that Bcl-2 is regulated in both a tissueand a temporal-speci®c manner. However, the mechanisms governing this tightly controlled transcriptional activity are unclear. Two promoter regions have been identi®ed in the 5'-untranslated region of the bcl-2 gene. P1, which is the major transcriptional promoter in most cell types examined so far (predominantly cells of hemopoietic lineage), is located 1386 ± 1423 bp upstream of the translation start site (Seto et al., 1988) . This promoter is TATA-less and GC-rich, and displays multiple start sites. It contains several SP1 and p1 recognition elements (Chen and Boxer, 1995; Seto et al., 1988; Wilson et al., 1996; Young and Korsmeyer, 1993) . P2, which is the predominant promoter in neuronal cells (Smith et al., 1998) , is located 1.3 kb downstream from P1, and contains a CCAAT box, an octamer motif (ATGCAAAG) and a TATA box (Seto et al., 1988) . Although, as mentioned above, little is known about the transcriptional regulation of bcl-2, some factors have been identi®ed that regulate its expression. In the case of the p1 promoter, the products of the cellular and viral myb genes (Frampton et al., 1996; Taylor et al., 1996) , the tumor suppressor gene product p53 (Miyashita et al., 1994; Miyashita and Reed, 1995) , the product of the Wilms tumor gene wt1 (Heckman et al., 1997; Hewitt et al., 1995) , and the HIV-1 Tat protein (Wang et al., 1999b) , for example, have been shown to regulate transcription. Very few studies have examined the p2 promoter, but recently the POU family member, Brn-3a, has been shown to transactivate transcription in neuronal cells (Smith et al., 1998) The transcription factor nuclear factor-kB (NF-kB) was ®rst identi®ed as a regulatory molecule essential for the activation of B-lymphocytes gene transcription (Baeuerle and Baltimore, 1996; Sen and Baltimore, 1986) . Since then, it has been found that NF-kB activity can be induced in most cell types upon treatment with a whole range of inducers, including cytokines such as tumor necrosis factor a (TNF-a) and interleukin-1 (Nabel and Baltimore, 1987; Sen and Baltimore, 1986) . In resting cells, NF-kB is sequestered in the cytoplasm in an inactive form bound to the inhibitor of kappa B (IkB) protein.
Upon stimulation, IkB is phosphorylated and proteolytically degraded or processed by proteases. This degradation of IkB activates NF-kB, which then forms dimers, translocates to the nucleus, and binds to target genes Verma et al., 1995) . To date, ®ve mammalian NF-kB family members have been cloned and characterized. They are NFkB1 (p50 or p105), NF-kB2 (p52 or p100), p65 or RelA, RelB and c-Rel (Baldwin, 1996) . These proteins can form homo-or heterodimers through their N-terminal Rel homology domains, which also function in DNA binding, nuclear localization and interaction with the inhibitor of kappa B (IkB) proteins (Jacobs and Harrison, 1998; Karin, 1999) . The predominant active NF-kB complex in mammalian cells is a heterodimer containing p50 and p65. This complex binds to a number of dierent DNA recognition sequences (Baeuerle, 1991; Grilli et al., 1993; Thanos and Maniatis, 1995) with the consensus DNA motif 5'GGGRNYYYCC3' (see Table 1 for extended DNA code).
Due to the observations that NF-kB is activated by many apoptotic stimuli, it was originally thought that this transcription factor is involved in cell death (Baeuerle and Henkel, 1994; Liou and Baltimore, 1993; Verma et al., 1995) . More recently, several groups have described an anti-apoptotic function for NF-kB (Van Antwerp et al., 1996; Wang et al., 1999a; Wu et al., 1996) . In a mouse gene knockout study, disruption of the relA locus leads to embryonic death due to extensive liver apoptosis (Beg et al., 1995) . Further, an anti-apoptotic role for NF-kB has been observed in response to TNFa, B cell stimulation, chemotherapy, and radiation Beg and Baltimore, 1996; Liu et al., 1996; Van Antwerp et al., 1996; Wang et al., 1999a) . Recent reports have identi®ed some of the genes regulated by NF-kB to suppress apoptosis (Stehlik et al., 1998; Wang et al., 1998; Wu et al., 1998) . For example, NFkB has been implicated in inducing expression of the death inhibitors c-IAP1, c-IAP2, and the TRAF1 (TNFR-associated factor 1) and TRAF2 factors, which results in the suppression of caspase-8 activation (Chu et al., 1997; Wang et al., 1998; You et al., 1997) . Moreover, the Bcl-2 family member A1/B¯-1 has recently been shown to be a transcriptional target of NF-kB (Wang et al., 1999a; Zong et al., 1999) . Finally, the over expression of Par-4 has been shown to decrease the DNA binding activity of NF-kB as well as diminish the expression levels of Bcl-2, suggesting that Par-4 exerts its pro-apoptotic activity by inhibiting the NF-kB pro-survival pathway (Camandola and Mattson, 2000) .
Recent studies have linked the expression of Bcl-2 to the development of the hormone-resistant phenotype of advanced prostate cancer (Colombel et al., 1993; McDonnell et al., 1992; Rao et al., 1995) . It also now appears that Bcl-2 expression may protect prostate cancer cells from many dierent apoptotic stimuli, such as hormone ablation, radiotherapy and chemotherapy including TNFa treatment (Apakama et al., 1996; Chaudhary et al., 1999; Huang et al., 1998; Mackey et al., 1998) . Studies examining the relationship between Bcl-2 and NF-kB in regulating TNF-a-induced apoptosis in prostate cancer cells found that inhibition of NF-kB nuclear export by the dominant-negative IkB mutant sensitized cells to TNF-a-induced apoptosis and exogenous over-expression of Bcl-2 eectively blocked this eect (Herrmann et al., 1997) . In this study we examine the transcriptional regulation of bcl-2 by NF-kB and its signi®cance for endogenous Bcl-2 expression in human prostate carcinoma cells following exposure to TNF-a.
Results
Identification of NF-kB transcription factor binding site(s) in the bcl-2 p2 promoter using recombinant NF-kB1
The location of NF-kB transcription factor binding site(s) in the bcl-2 promoter regions was identi®ed by DNase I footprinting analysis using puri®ed recombinant p50 (NF-kB1) protein (Figure 1 ). Protection was clearly observed in one region (site 1) of the bcl-2 p2 promoter ( Figure 1 , lane 2) and, consistent with this observation, it was noted that the sequence of this region contained an element with 80% identity with the NF-kB consensus sequence (Table 1) . A less convincing second site (site ?) was also identi®ed but only a poor match to the consensus sequence was found in this region (Table 1 , referred to as site 2). No footprints were observed in the bcl-2 p1 promoter region (data not shown).
To examine further these putative NF-kB sites, gel retardation and supershift analysis of these individual regulatory elements were performed. Initially, doublestranded oligonucleotides corresponding to the puta- Identity indicates the number of nucleotides, which are identical to the 10 nucleotide NF-kB consensus sequence.
c Coordinates are determined from sequence retrieved from GENBANK (accession no. M13994) with the A nucleotide of the ATG designated as +1. From sequence (Lenardo and Baltimore, 1989; Nabel and Verma, 1993; Thanos and Maniatis, 1995; Virbasius et al., 1993 ). . This analysis demonstrated that the bcl-2 p2 site 1 but not site 2 speci®cally interacted with p50, forming complexes (A and B), which comigrated with the complexes formed between the NF-kB consensus sequence and p50 ( Figure 2, lane 2) . Furthermore, all the complexes formed between the double-stranded oligonucleotides and p50 were inhibited by the addition of unlabeled consensus NF-kB doublestranded oligonucleotide as competitor (Figure 2 , lane 1) but not by the addition of an unrelated sequence hepatocyte nuclear factor 3 (HNF3) (Figure 2 , lanes 8 and 9). In addition, no complex was formed between the labeled consensus cAMP response element (CRE) double-stranded oligonucleotide and p50 (Figure 2 , lanes 10 and 11) supporting the speci®city of the NFkB-p50 complex formation. An antibody to p50 generated a supershift complex for both the consensus NF-kB site (Figure 2 , lanes 3 and 9) and the bcl-2 p2 site 1 (Figure 2 , lane 5), and this complex appears to originate from complex A, not B. We propose that A is a homodimer complex of p50 and B is an in vitro artifact due to the high levels of p50 compared with the in vivo situation where p50 is predominantly present as a p65/p50 heterodimer. Thus, these results indicate that p50 speci®cally binds the site 1 region of bcl-2 p2 but not site 2.
Characterization of the DNA binding proteins in nuclear cell extracts from TNF-a treated LNCaP or WEHI 231 cells that interact with the bcl-2 p2 promoter putative NF-kB binding site 1 DNase I footprinting and gel retardation analysis have demonstrated that puri®ed recombinant p50 binds to the bcl-2 p2 promoter site 1. However, the analysis with recombinant proteins does not indicate the nature of the factor(s) that interact with these sequences in vivo and, in particular, it is known that a p65/p50 heterodimer is the predominant complex in cells. To examine this issue, the double-stranded oligonucleotide spanning the putative bcl-2 p2 promoter NF-kB site 1 was examined for its ability to bind nuclear proteins present in the TNF-atreated prostate carcinoma LNCaP cells or the WEHI 231 immature B cell lymphoma line ( Figure 3 ). The WEHI 231 cells are known to be a good source of the NFkB transcription factor family members . The bcl-2 promoter site 1 speci®cally interacted with proteins present in the WEHI 231 nuclear extracts ( Figure 3A , lane 5) and in LNCaP ( Figure 3B ), forming complexes, which comigrated with the complexes formed with the consensus NF-kB site ( Figure 3A , lanes 2 and 3B). The nature of the DNA-protein complexes formed between the putative NF-kB site 1 and the consensus NFkB site was further investigated by supershift analysis. Nuclear extracts from TNF-a-treated WEHI 231 cells ( Figure 3A ) or LNCaP cells ( Figure 3C ) were incubated with antibody speci®c for either p50 or p65. With the addition of the anti-p50 antibody the p65/p50 complex, P-labeled double-stranded oligonucleotide probes bcl-2 p2 site 1 (lane 4 and 5), site 2 (lane 6 and 7) and consensus NF-kB (lane 1, 2, 3, 8 and 9) were analysed for their ability to form gel retardation and supershift complexes with recombinant p50. The rabbit anti-p50 antibody (Calbiochem-Novabiochem Corp.) was incubated with the extract analysed as indicated. The unlabeled NF-kB consensus sequence double-stranded oligonucleotide was used as competitor in lane 1 and an unrelated unlabeled competitor hepatocyte nuclear factor (HNF-3) was added in lane 8 and 9 to demonstrate the speci®city of the observed complex. The labeled cAMP response element (CRE) consensus sequence double-stranded oligonucleotide was also used to test the speci®city of the interaction. The autoradiograph shows one representative experiment for both the consensus NF-kB ( Figure 3A , lane 3 and Figure 3C upper panel, left) and the bcl-2 p2 site 1 ( Figure  3A , lane 6 and Figure 3C upper panel, right), are supershifted to the position indicated with the arrow (right side of autoradiograph). Similarly, when the antip65 antibody is incubated with the nuclear extracts a supershifted complex is formed for both the consensus NF-kB ( Figure 3A , lane 4 and Figure 3C lower panel, left) and the bcl-2 p2 site 1 ( Figure 3A , lane 7 and Figure  3C lower panel, right). These data suggest that under these conditions the p65/p50 heterodimer is the main complex detected. The interactions do appear to be speci®c as all complexes formed between the doublestranded oligonucleotides and the nuclear extracts were inhibited with unlabeled consensus NF-kB oligonucleotide as competitor ( Figure 3A , lanes 1 and 8 for consensus NF-kB and bcl-2 p2 site 1, respectively). Noticeable, the interactions were also inhibited by unlabeled bcl-2 p2 promoter site 1 but not by the mutated site 1 or HNF3 ( Figure 3B ) supporting their speci®city.
No supershifted complexes were observed with an anti-sp1 irrelevant antibody (data not shown). Thus this supershift analysis with the anti-p65 and anti-p50 antibodies supplies further physical evidence that the bcl-2 p2 site 1 does indeed bind NF-kB complexes.
Transactivation of transcription by NF-kB from the bcl-2 p2 promoter is mediated through the bcl-2 p2 site 1
The physical data discussed above demonstrates that the bcl-2 p2 promoter site 1 can bind NF-kB. However, to determine whether this NF-kB binding site can, in fact, activate transcription, site 1 was Figure 3 Gel retardation and complex supershift analysis of the bcl-2 p2 promoter regulatory regions with extracts from TNF-atreated LNCaP and WEHI cells and antibodies speci®c for NFkB. (A) the 33 P-labeled double-stranded oligonucleotide consensus NF-kB (lanes 1 ± 4) and the bcl-2 p2 site 1 (lanes 5 ± 8) probes were analysed for their ability to form supershifted complexes with DNA-binding proteins in nuclear extracts from TNF-atreated WEHI 231 cells (ProÈ sch et al., 2000) . The anti-p50 antibody was incubated with the extracts analysed in lanes 3 and 6 (Santa Cruz Biotechnology, Inc.) and the anti-p65 antibody was incubated with the extracts analysed in lanes 4 and 7 (Rocklands Immunochemicals, Inc.). The unlabeled consensus NF-kB sequence double-stranded oligonucleotide was used as competitor DNA in lanes 1 and 8 to demonstrate the speci®city of the observed complexes. The arrows indicate the positions of the retarded protein-DNA complex (p65/p50 heterodimer) and supershifted complexes. The autoradiograph shows one representative experiment. (B) gel retardation analysis of the bcl-2 p2 promoter site 1 with extracts from TNF-a-treated LNCaP cells. The double-stranded oligonucleotide consensus NF-kB (lanes 1 ± 5) and the bcl-2 p2 site 1 (lanes 6 ± 10) were analysed as described in (A) except that nuclear extracts from TNF-a-activated-LNCaP cells were used in this assays and no antibodies were included. Where indicated, unlabeled double-stranded oligonucleotides where added to demonstrate the speci®city of the complex. Consensus, NF-kB consensus oligonucleotide; HNF3, hepatocyte nuclear factor 3; site 1, bcl-2 p2 site 1; site 1 M, bcl-2 p2 mutated site 1. (C) the (Figure 4 ). The bcl-2 p2 site 1 (site1), bcl-2 p2 site 2 (site2) as negative control, and the consensus NF-kB (kB) synthetic promoter constructs were tested for their transcriptional activity in the Hela S3 cell line in the presence (+) and absence (7) of the p50/p65 expression vectors (NF-kB). The activities are shown relative to the activity of the synthetic construct containing two copies of the consensus NF-kB oligonucleotide (construct kB (2)) in the presence of exogenously expressed p50/p65 (+NF-kB). The level of transcription from this construct was increased 10-fold in the presence of the p50/p65 expression vectors and was comparable to the levels of transactivation observed for the construct containing two bcl-2 p2 sites 1 (site1 (2)). The kB (4) and site1 (4) constructs also show comparable levels of activation of transcription (approximately 18-and 14-fold transactivation). In contrast, the site 2 constructs and the control vector pTATA show no transactivation, thus supporting the physical evidence and indicating that, at least in the context of a minimal promoter, the bcl-2 p2 site1 is a functional NF-kB site.
To test whether exogenously expressed NF-kB can transactivate transcription from the intact bcl-2 p2 promoter, the p2 promoter construct (p2LUC) that contains a downstream ®re¯y luciferase gene, was examined for activity in the presence (+) and absence (7) of exogenously expressed p65/p50 (NF-kB) in Hela S3 cells ( Figure 5 ). The transcriptional activities are reported relative to the p2LUC construct in the absence of NF-kB, which is designated as having a relative activity of 1.0, and the exogenously expressed NF-kB was found to transactivate transcription sixfold from the p2 promoter (p2LUC+NF-kB). To determine whether this activity could be located to the bcl-2 p2 site 1, constructs containing mutated site 1 (p2M1LUC) and site 2 (p2M2LUC), as control, were examined for their transcriptional activity in the presence (+) and absence (7) of p50/p65 (NF-kB). The mutation of the bcl-2 p2 site 1 essentially eliminated NF-kB-dependent transcription as transcriptional activity from p2M1LUC was found to be essentially the same in the presence or absence of exogenously expressed NF-kB (c.f. p2M1LU-C+and7NF-kB). The dierence observed between p2LUC and p2M1LUC in the absence of exogenously expressed NF-kB is presumably due to the presence of endogenous NF-kB in the Hela S3 cells. In contrast, the loss of the bcl-2 p2 site 2 (p2M2LUC) had no signi®cant eect on the transactivation of the bcl-2 p2 promoter by NF-kB. promoter by NF-kB and abolition of this eect by site-directed mutagenesis of the putative site 1. The constructs p2LUC contains the bcl-2 p2 promoter sequence from 7754 to +1 located directly 5' to the promoterless ®re¯y luciferase (LUC) reporter gene in pbasic (Promega), such that the bcl-2 p2 promoter governs the expression of the LUC gene. The p2M1LUC and p2M2LUC plasmids containing mutated sites 1 or 2, respectively, were generated from p2LUC using the GeneEditor site-directed mutagenesis kit (Promega). The relative activity of the constructs in Hela S3 cells were examined in the presence (+) and absence (7) of exogenously expressed p50/p65 by using the expression vectors pCMVp50 and pCMVp65. The transcriptional activities are reported relative to the p2LUC construct in the absence of NF-kB, which is designated as having a relative activity of 1.0. pRL-TK was used to correct for transfections eciencies. These results are the average of four separate experiments and the error bars indicate the standard deviation Figure 4 Functional analysis of the putative bcl-2 p2 promoter NF-kB sites in the context of a minimal promoter. The constructs examined contain the consensus NF-kB sequence (kB), the bcl-2 p2 site 1 (site 1), and the bcl-2 p2 site2 (site2) double-stranded oligonucleotides cloned into the minimal promoter construct pTATA (see scheme on top). The number of copies of the oligonucleotide in the construct is shown in parentheses in the constructs name. The relative activities of the constructs in Hela S3 cells were examined in the presence (+) and absence (7) of exogenously expressed p50/p65 (NF-kB) by using the expression vectors pCMVp50 and pCMVp65. The transcriptional activities are reported relative to the pNF-kB (2) construct in the presence of NF-kB, which is designated as having a relative activity of 1.0. pRL-TK was used to correct for transfections eciencies. These results are the average of three separate experiments and the error bars indicate the standard deviation TNF-a treatment and Bcl-2 expression in the human prostate carcinoma LNCaP cells TNF-a has been shown to contribute to the progression of several cancers and as prostate cancer patients experiencing a relapse in their disease have been found to express high levels of TNF-a in their serum (Nakashima et al., 1998), it appears possible that TNF-a may play a role in the progression of prostate cancer. To examine the eect of TNF-a on Bcl-2 expression in human prostate carcinoma cells, hormone-responsive LNCaP cells were stimulated with 10 ng/ml of TNF-a either in the absence (7H) or presence (+H) of hormone (6a-¯uorotestosterone) ( Figure 6 ). The expression of Bcl-2 was augmented in the absence of hormone (7) compared to in the presence of hormone (+) under all conditions. Furthermore, this Bcl-2 expression was further increased by TNF-a treatment of cells cultured in the absence of hormone. To examine if this increase in response to TNF-a involved the TNF-a/NF-kB antiapoptotic pathway as suggested by the bcl-2 promoter studies presented above, the eect of NF-kB inhibitors (Bay 11-7082 and the NF-kB inhibitor peptide) was examined. Bay 11-7082 is an inhibitor of the cytokineinduced IkB-a phosphorylation, an event essential for NF-kB activation as described earlier. The NF-kB inhibitor peptide is a cell-permeable inhibitory peptide that contains the nuclear localization sequence (residues 360 ± 369) of NF-kB1 linked to the hydrophobic region of the signal peptide of Kaposi ®broblast growth factor (K-FGF). With either inhibitor the increase of Bcl-2 expression observed with TNF-a alone was inhibited supporting the involvement of the Figure 5 legend). After transfection cells were cultured in normal growth medium for 24 h and then were transferred to medium containing 10% charcoal-stripped serum either in the absence (7) or presence (+) hormone (0.5 nM 6a-¯uorotestosterone) and were stimulated with 10 ng/ml of TNF-a. The transcriptional activities are reported relative to the p2LUC construct in the absence of TNF-a and presence of hormone, which is designated as having a relative activity of 1.0. (B) LNCaP cells were transfected with either p2LUC containing the full p2 promoter region, or the control vector pbasic and the pCMV IkB dominant negative (IkB DN+) or the empty vector (IkB DN 7). LNCaP cells were cultured in the absence of hormone and stimulated with TNF-a as described for (A). The transcriptional activities are reported relative to the p2LUC construct in the presence of TNF-a and IkB DN, which is designated as having a relative activity of 1.0. In all cases, pRL-TK was used to correct for transfections eciencies. The results in (A and B) are the average of three separate experiments and the error bars indicate the standard deviation Figure 6 Augmented expression of Bcl-2 in response to hormone withdrawal is further increased in the presence of TNF-a. LNCaP human prostate carcinoma cells were cultured in medium containing 10% charcoal-stripped serum in the presence (+H) or absence (7H) of hormone (0.5 nM 6a-¯uorotestosterone) overnight, before the addition of NF-kB inhibitors and/or TNF-a. The inhibitors (Bay 11-7082 [10 mM] and cell-permeable NF-kB inhibitory peptide [100 mg/ml]) or the cell-permeable NFkB control peptide [100 mg/ml] were incubated with cells for 15 min at 378C before the addition of TNF-a (10 ng/ml). The incubation at 378C was then continued for a further 6 h before lysing the cells and analysing the proteins (100 mg) by immunoblotting against Bcl-2. The equal loading was con®rmed by Ponceau S solution (Sigma Chemical Co) staining Oncogene Transcriptional activation of bcl-2 by NF-kB SD Catz and JL Johnson NF-kB pathway. The lower level of expression of Bcl-2 observed in the presence of hormone was almost completely abated by the addition of the NF-kB inhibitors, suggesting that NF-kB activation is required for Bcl-2 expression in the presence of hormone. The cell-permeable control peptide which contains an inactive, mutated form of the nuclear localization sequence of NF-kB1 linked to K-FGF had no or little eect on the augmented expression of Bcl-2 following TNF-a stimulation.
Transactivation of transcription from the bcl-2 p2 promoter in LNCaP cells in response to hormone withdrawal and TNF-a stimulation
To examine the eect of hormone withdrawal and TNF-a stimulation on the bcl-2 p2 promoter activity in LNCaP cells, transient transfection experiments were performed using the p2 promoter construct (p2LUC) that contains the full-length bcl-2 p2 promoter upstream of the ®re¯y luciferase gene ( Figure 7A ). The transcriptional activities are reported relative to the p2LUC construct in the absence of TNF-a (7TNF-a) and presence of hormone (+hormone), which is designated as having a relative activity of 1.0.
Hormone withdrawal was found to increase transcriptional activity of the p2 promoter eightfold and TNF-a treatment in the absence of hormone dramatically augmented promoter activity, 40-fold over p2LUC in absence of TNF-a and presence of hormone. (The control vector pbasic displayed negligible activity under all conditions). These results con®rm the results obtained for Bcl-2 protein expression in LNCaP cells. To further demonstrate that the transactivation of transcription from the bcl-2 p2 promoter in LNCaP cells in response to hormone withdrawal and TNF-a stimulation is mediated by NF-kB, the transcriptional activity of the bcl-2 p2 promoter was evaluated under these conditions, and following co-transfection of the LNCaP cells with the pCMV IkB dominant negative construct (Upstate Biotechnology). This vector expresses a non-phosphorylatable, non-degradable IkB ( Figure 7B) . The results presented here show that the transactivation of the bcl-2 p2 promoter in TNF-aactivated LNCaP cells is inhibited by the ablation of the NF-kB signaling. All together, this data suggests a predominant role of the TNF-a/NF-kB pathway in the transcriptional regulation of bcl-2 in prostate cancer cells via the p2 promoter.
Discussion
Presented here is the ®rst direct evidence that bcl-2 is transcriptionally regulated by NF-kB and this activity is mediated through a functional NF-kB site identi®ed in the bcl-2 p2 promoter. Increasing evidence is emerging that bcl-2 expression is linked to the antiapoptotic function of NF-kB, but until now the only direct link between bcl-2 and NF-kB was the recent observation that Bcl-2 activates NF-kB through the degradation of the inhibitor IkBa (de Moissac et al., 1998 (de Moissac et al., , 1999 . This previous observation that Bcl-2 activates NF-kB and the evidence presented here that NF-kB transactivates bcl-2 expression suggest a very potent mechanism for the suppression of apoptosis. Over the past few years it has become apparent that TNF exerts a neuroprotective eect in response to brain injury. For instance studies using mice de®cient in TNF receptors demonstrated that endogenous TNF protects neurons against ischemic and excitotoxic insults (Bruce et al., 1996; Cheng et al., 1994) . NFkB has now been shown to be involved in this neuroprotection by several groups using a decoy kB DNA approach (Mattson et al., 1997) . Furthermore, this neuroprotective eect of TNF, which involves activation of NF-kB, has now been shown to be a result of an increase in Bcl-2 and Bcl-x expression (Tamatani et al., 1999) . Tamatani et al. showed that TNF protected neurons against hypoxia-and nitric oxide-induced toxicity and up-regulated Bcl-2 and Bclx expression (Tamatani et al., 1999) . Bcl-2 or Bcl-x anti-sense oligonucleotides, which inhibit up-regulation of Bcl-2 and Bcl-x, respectively, inhibited the neuroprotective eect induced by TNF. Moreover, this upregulation of Bcl-2 and Bcl-x expression was completely inhibited by the dominant-negative IkB mutant (Van Antwerp et al., 1996; Wang et al., 1996) , suggesting that Bcl-2 and Bcl-x are target genes for NF-kB. The work presented here identi®es the bcl-2 p2 promoter as a direct transcriptional target for NF-kB, and is consistent with the recent report that transcription is predominantly initiated from the bcl-2 p2 promoter in neuron cells (Smith et al., 1998) , con®rming the involvement of Bcl-2 and NF-kB in the protective eect of TNF observed in neuron cells.
Many studies have linked the expression of Bcl-2 to the development of the hormone-resistant phenotype of advanced prostate cancer (Baltaci et al., 2000; Chaudhary et al., 1999; Colombel et al., 1993; McDonnell et al., 1992; Rao et al., 1995) . Recently, it also appears that Bcl-2 expression may protect prostate cancer cells from many dierent apoptotic stimuli, including hormone ablation, radiotherapy and chemotherapy (Apakama et al., 1996; Chaudhary et al., 1999; Huang et al., 1998; Mackey et al., 1998) . Hormone ablation therapy has been a major treatment for prostate cancer for many years (Westin and Bergh, 1998) . Although 70% of patients initially respond to this treatment, it is essentially palliative because, with time, almost all tumors will progress to an androgen independent state that is rapidly fatal (Sinha et al., 1977) . An understanding of the molecular mechanisms that control this progression from hormone dependent to hormone independent is a key factor in the eective treatment of prostate cancer. It is proposed by many groups that the growth of the hormone responsive prostate carcinoma cell line, LNCaP, in the absence of hormone mimics the conditions of hormone ablation therapy of prostate cancer (Lu et al., 1999) . The increased expression of Bcl-2 in LNCaP cells in response to hormone removal described here has been observed with in vivo castration studies of rat prostate epithelium cells, thus con®rming the similarity in the two situations (Perlman et al., 1999) . This up regulation of Bcl-2 expression and subsequent down regulation of apoptosis in response to hormone ablation therapy now appears to be a possible trigger of the progression from the hormone dependent to hormone independent state. It has been reported elsewhere that growth of LNCaP cells in hormone free medium results in arrest of cell proliferation rather than apoptosis (Saeed et al., 1997) , thus this could allow the hormone responsive cells time to gain mutations that would be responsible for the switch from hormone responsive to hormone unresponsive and release from cell cycle control. Recently it has been reported that prostate cancer patients experiencing a relapse in disease after hormone ablation therapy have increased serum TNF-a levels compared with untreated patients or patients in remission (Nakashima et al., 1998) . Therefore, the increase in Bcl-2 expression reported here in response to TNF-a in the absence of hormone is very signi®cant to the disease state. If the LNCaP cells do mimic androgen-responsive prostate cancer before its relapse into hormone-refractory phase as proposed earlier then these results suggest that a similar phenomenon could take place during hormone ablation therapy. The elevated serum levels of TNF-a of relapsed patients in combination with the withdrawal of hormone in hormone ablation therapy appear to be a negative indicator for the progression of prostate cancer as increased levels of Bcl-2 have repeatedly been associated with the more aggressive, therapy resistant advanced stage of the disease (Bubendorf et al., 1996; Chaudhary et al., 1999; Mackey et al., 1998; Scherr et al., 1999) . The identi®cation of bcl-2 as a direct transcriptional target of NF-kB in combination with the LNCaP studies discussed above provide evidence that endogenous Bcl-2 expression is up regulated in prostate cancer cells via the TNF-a-NF-kB signal transduction pathway and support this anti-apoptotic pathway as a suitable target for gene therapy in prostate cancer. The report here that TNF-a increases bcl-2 p2 promoter activity and Bcl-2 expression was only observed in the absence of hormone and that inhibition of NF-kB in the presence of hormone completely ablated Bcl-2 expression suggests that gene therapy to inhibit NF-kB activity could be successful in the presence of hormone. With the lower level of expression of Bcl-2 in this condition it is proposed that the prostate cancer cells would once again be sensitive to radio-and chemo-therapy including the patients own natural TNF-a.
Materials and methods

Cell culture, transfections and luciferase assays
The immature B cell lymphoma line, WEHI 231, and the human cervical carcinoma cell line, Hela S3 (ATCC), were maintained in Dulbecco's modi®ed Eagle's medium (DMEM), supplemented with 10% fetal calf serum, and 0.45% glucose (Gibco Laboratories), at 378C in 5% CO 2 /air. WEHI 231 cells were supplemented with 50 mM b-mercaptoethanol, as described elsewhere (McCormack et al., 1984) . Prior to treatment, WEHI 231 cells were diluted to a density of 3.5610 5 cells/ml with fresh medium and incubated for 5 h. The human prostate carcinoma cell line LNCaP-FGC (ATCC), which are referred to in this report as LNCaP, was cultured in RPMI-1640 supplemented with 10% of either fetal bovine serum or charcoal-stripped fetal bovine serum (Gemini Bioproducts), 50 units/ml penicillin and 50 mg/ml streptomycin.
Transfections were performed in 6-well plates as previously described (Graham and van der Eb, 1973; Sorge et al., 1984) . The transfected DNA mixture comprised of 5 mg of the ®re¯y LUC plasmid (see cloning and mutagenesis section below) and 250 ng of pRL-Tk (Promega), which served as an internal control for transfection eciency. pRL-TK directs expression of the renilla luciferase (RL) gene using the herpes simplex virus thymidine kinase promoter. Where appropriate the DNA mixture also included 100 ± 250 ng of the NF-kB expression vectors (pCMV-p50 and pCMV-p65), the control vector pCMV-PA (generous gift of LR Faust) or the IkB dominant negative cDNA pUSE-IkB (S32A/S36A) (Upstate Biotechnology). Cell extracts were prepared 48 h after transfection and assayed for ®re¯y and renilla luciferase activity using the stop and glo kit (Promega) as instructed by the manufacturer.
Cloning and mutagenesis
The various steps in the cloning of the plasmid constructs were performed by standard techniques (Sambrook et al., 1989) . The bcl-2 p2 promoter DNA fragment from 7754 to+1 was generated by PCR using genomic DNA derived from Hela S3 cells and oligonucleotides CGAGCTCTTGA-GATCTCCGGTTGGGATTCC (coordinates 7754 to 7725) and ccccaagctTCCTTCCCAGAGGAAAAGCAAC-GGGGGCCAACGGCACC (coordinates 737 to +1) (see Table 1 footnotes). The PCR product was cloned into the polylinker of pbasic (Promega) to generate p2LUC. The p2M1LUC and p2M2LUC plasmids containing mutated sites 1 or 2, respectively, were generated from p2LUC using the GeneEditor site-directed mutagenesis kit (Promega) as speci®ed by the manufacturer. The M1 mutation converted the 10-nucleotide putative NF-kB site 1 sequence located between 7174 to 7165 from GGGAAACACC to ATCGG-TACCT. The M2 mutation converted the 10-nucleotide site 2 sequence located between 7200 to 7209 from GGAATTG-GAA to ATCGGTACCT. pTATA was generated by inserting a double-stranded oligonucleotide containing the bcl-2 p2 TATA-box element (TATAA) into the polylinker of pbasic, in the same orientation as the TATA-box element occurs in the promoter. The plasmids kB (2), kB (4), site1 (2), site1 (4), site2 (2) and site2 (4) were constructed by inserting two or four synthetic double-stranded oligonucleotides into the SalI site of pTATA (as indicated in the construct designation). The sequences of all constructs were veri®ed by dideoxynucleotide sequencing (Sanger et al., 1977) . The pCMVp50 and pCMVp65 vectors express p50 and p65, respectively, by using the cytomegalovirus immediate-early promoter (pCMV).
Nuclear and whole cell extracts
Nuclear extracts were prepared from LNCaP or WEHI 231 essentially as described (ProÈ sch et al., 2000) . The cells were Oncogene Transcriptional activation of bcl-2 by NF-kB SD Catz and JL Johnson treated with TNF-a (50 ng/ml) (Sigma) for 2 h to overnight at 378C before preparation of the extracts. LNCaP cell extracts were prepared essentially as described elsewhere (Miyake et al., 1998) . For Bcl-2 expression analysis cells were incubated in medium containing 10% charcoal-stripped serum in the presence or absence of hormone (0.5 nM 6a-uorotestosterone) overnight before the addition of NF-kB inhibitors and/or TNF-a. The inhibitors (Bay 11 ± 7082 or NF-kB inhibitory peptide) or the control peptide (all from Biomol) were incubated with cells for 15 min at 378C before the addition of TNF-a (10 ng/ml). The incubation at 378C was then continued for a further 6 h before the cells were lysed and analysed by immunoblotting.
Immunoblot analysis
Expression of Bcl-2 was examined essentially as performed elsewhere (Miyake et al., 1998) . Samples containing 100 mg of protein were subjected to SDS ± PAGE and transferred to nitrocellulose membrane. The ®lters were blocked in PBS containing 5% nonfat milk powder at room temperature for 1 h and then incubated in for 3 h at room temperature with a 1 : 100 dilution of an anti-bcl-2 mouse monoclonal antibody (Santa Cruz, CA, USA). The membranes were then incubated for 1 h at room temperature with alkaline phosphatase-conjugated anti-mouse IgG antibody (Caltag) and speci®c proteins were visualized with a colorimetric system (BCIP/NBT) following the manufacturer's instructions (Biorad). The equal loading was con®rmed by Ponceau S solution (Sigma Chemical Co., St Louis, MO, USA) staining.
DNase I footprinting, electromobility gel shift and supershift assays
The DNase I footprinting reactions were performed as described previously (Briggs et al., 1986; Johnson et al., 1995) . The reactions contained 1 ± 5 ng of end-labeled DNA fragment in a 100 ml reaction mixture containing 10 mM Trishydrochloride (pH 7.9), 50 mM KCl, 0.5 mM EDTA, 1 mM DTT, 0.5 mM PMSF, 10% (vol/vol) glycerol, 1 mg of poly[d(I-C)] and puri®ed p50 (Promega). Binding was carried out for 15 min at 08C followed by 2 min and then stopped by the addition of 100 ml of 1% (wt/vol) NaDodSO 4 , 20 mM EDTA, 200 mM NaCl containing 250 mg/ml of tRNA. The mixture was then extracted with phenol, precipitated with ethanol, and analysed by 6% urea-acrylamide sequencing gel electrophoresis and autoradiography.
Electromobility gel shift assays were performed as described previously (Dignam et al., 1983; Johnson and McLachlan, 1994) .
33 P-labeled double-stranded oligonucleotides (1 ng) representing putative NF-kB sites and controls (see plasmid constructions) were incubated with either puri®ed p50 (Promega), or 10 mg of nuclear extract (as described in Figure legend) , prior to 4% polyacrylamide gel electrophoresis and autoradiography. When gel retardation competition analysis was performed, the extract or puri®ed protein was preincubated with 1 mg of cold double-stranded competitor oligonucleotide for 15 min prior to the addition of the 33 P-labeled double-stranded oligonucleotides. Supershift analysis was performed by incubating the nuclear extract, or puri®ed protein with 2 ml of a rabbit anity puri®ed polyclonal antibody raised against p50 or p65 (Santa Cruz Biotechnology, Inc. and Rocklands Immunochemicals, Inc., respectively) for 1 h to overnight at 48C prior to the addition of the 33 P-labeled double-stranded oligonucleotide. The oligonucleotide pairs used were TCGAGGGGGAAA-CACCAG and TCGACTGGTGTTTCCCCC (bcl-2 p2 site 1, coordinates 7176 to 7163 plus SalI overhang), TCGAAA-GGAATTGGAATA and TCGATATTCCAATTCCTT (bcl-2 p2 site 2, coordinates 7211 to 7198 plus SalI overhang), TCGAGGATCGGTACCTAG and TCGACTAGGTACCG-ATCC (bcl-2 p2 site 1 mutant), AGTTGAGGGGACTT-TCCCAGGC and GCCTGGGAAAGTCCCCTCAACT (consensus NF-kB), (Santa Cruz Biotechnology, Inc.), GTTGATGACGTCAAGGC and GCCTTGACGTCATCA-ACT (control consensus CRE), and TCGACACTATTTA-CACACTCTATG and TCGACATAGAGTGTGTAAATA-GTG (hepatitis B virus large surface antigen HNF3 site plus SalI overhang) (Johnson et al., 1995) .
